viewReNeuron Group PLC

ReNeuron makes key business development hire as it looks to build on licensing deals

ReNeuron Group PLC's (LON:RENE) Michael Hunt caught up with Proactive London's Andrew Scott following the news this morning that they've appointed a business development director, Nick Adams,  to help them build on the licence deals signed with Chinese giant Fosun Pharma.

Hunt also discusses the recent release of their preliminary results covering the 12 months to the end of March 2019.

One of the year's highlights came in February, when they reported positive initial data from the mid-stage study of its retinitis pigmentosa treatment.

Quick facts: ReNeuron Group PLC

Price: 173 GBX

Market: LSE
Market Cap: £55.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...



ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18

2 min read